Vertex is seeking partnerships
Vertex business development
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company´s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies.
Vertex´s product pipeline is focused on:
- viral diseases
- autoimmune diseases
- bacterial infection.
Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. In addition to forging new collaborations, Vertex is actively pursuing in-licensing and acquisition opportunities that could serve to accelerate the Company´s business strategy.
Vertex´s in-licensing efforts are focused on later-stage products (Phase II or III) in a wide range of therapeutic areas, as well as earlier-stage products (e.g. preclinical or Phase I) in specific therapeutic areas that are core to the Company´s commercial goals.
Vertex is focused on structuring in-licensing deals and acquisitions that meet the strategic objectives of both parties and build shareholder value. With a strong cash position and a world-class research and development team, Vertex possesses the resources and commitment to ensure the success of in-licensed products.